Waiting Too Long: How Systemic Gaps Delay G6PD Diagnosis and What Patients Can Do Right Now

For a condition that affects an estimated 400 million people worldwide—including millions of Americans—glucose-6-phosphate dehydrogenase (G6PD) deficiency remains remarkably underdiagnosed. Patients often cycle through emergency rooms, hematology consultations, and primary care visits before a clinician finally orders the right test. The consequences of that delay are not merely frustrating; they can be life-threatening, particularly when an undiagnosed individual is prescribed a medication that triggers a hemolytic crisis.

Understanding why those delays happen is the first step toward dismantling them.

A Screening System Built With Blind Spots

In the United States, newborn screening programs vary significantly by state. While all fifty states screen for conditions such as phenylketonuria and congenital hypothyroidism, G6PD deficiency is included in only a handful of state panels. The American College of Medical Genetics and Genomics has not universally mandated its inclusion, leaving the decision to individual state health departments that often weigh cost considerations against prevalence data derived from predominantly white reference populations.

This creates a foundational problem: the communities most likely to carry the G6PD gene variant—people of West African, Mediterranean, Middle Eastern, South Asian, and Southeast Asian descent—are also the communities least likely to be identified through newborn screening. A child born in Mississippi or Georgia, where G6PD prevalence among African American males can reach 10 to 13 percent, may never receive a screening test unless a clinician specifically orders one.

The result is a generation of patients who enter adulthood carrying a genetic condition they know nothing about.

Provider Unfamiliarity: A Gap in Medical Education

Even when patients present with symptoms consistent with G6PD deficiency—jaundice, dark urine, sudden-onset anemia, fatigue following an illness or new medication—many clinicians do not immediately consider the diagnosis. G6PD deficiency receives limited coverage in most US medical school curricula, and continuing education resources for practicing physicians are sparse.

Patient accounts collected by advocacy organizations consistently describe the same pattern: a hemolytic episode is treated as an isolated event, the underlying enzyme deficiency is never tested, and the patient is discharged without a diagnosis. Months or years later, the cycle repeats.

Dr. Marcus Webb, a hematologist practicing in Atlanta, has observed this firsthand. "I see patients in their thirties and forties who have had three or four hospitalizations for hemolytic anemia," he noted in a 2022 conference presentation on rare hematologic disorders. "In some cases, no one had ever ordered a G6PD enzyme activity test. It's not negligence—it's a knowledge gap that the system has not prioritized closing."

The Intersection of Race, Genetics, and Medical Inequity

The demographic profile of G6PD deficiency is inseparable from the broader conversation about racial disparities in American healthcare. Because the condition is most prevalent among communities of color, it has historically received less research funding, fewer public health campaigns, and less institutional attention than conditions that primarily affect white populations.

This inequity compounds at the clinical level. Studies examining diagnostic disparities have found that Black patients presenting with ambiguous symptoms are less likely to receive comprehensive diagnostic workups than their white counterparts. When a condition like G6PD deficiency requires a clinician to connect subtle, intermittent symptoms to a genetic cause, implicit bias and structural under-resourcing can widen the diagnostic gap further.

Access to genetic counseling—a resource that can help patients and families understand hereditary conditions and advocate for appropriate testing—is also unevenly distributed. Rural communities, uninsured individuals, and those relying on safety-net health systems frequently lack access to these services entirely.

What Misdiagnosis Looks Like in Practice

Consider the experience of Darnell, a 28-year-old man from Houston who spent nearly a decade being treated for "recurrent anemia of unclear etiology." He was prescribed iron supplements that provided no benefit, underwent multiple bone marrow evaluations, and was at one point evaluated for sickle cell disease. It was not until a new primary care physician reviewed his full history and ordered a G6PD enzyme activity test that the diagnosis was finally made.

"I had been told my anemia was a mystery for so long that I stopped questioning it," Darnell recalled. "Once I had the diagnosis, everything made sense—the episode after I took that antimalarial medication on a trip, the jaundice I had as a baby that my mother mentioned. The pieces were all there."

Darnell's story is not exceptional. It is representative of a pattern that plays out across the country, in emergency departments and primary care offices, in urban hospitals and rural clinics.

Strategies for Advocating During Medical Visits

Patients and caregivers who suspect G6PD deficiency—or who have a family history of the condition—should approach medical appointments with a clear advocacy strategy. The following steps can meaningfully accelerate the diagnostic process.

Request the test by name. The G6PD enzyme activity test is a standard laboratory test available at most clinical laboratories. Patients have the right to ask their physician to order it directly. If a physician is unfamiliar with the test, providing printed information from a reputable source—such as this website—can facilitate the conversation.

Document your symptom history in writing. A written timeline of hemolytic episodes, including dates, associated medications or foods, and how symptoms resolved, gives clinicians the clinical narrative they need to connect isolated events to a pattern.

Ask about family history testing. G6PD deficiency is X-linked, meaning it follows predictable inheritance patterns. If one family member is diagnosed, others may benefit from testing. Requesting a referral to a genetic counselor can help the entire family understand their risk.

Bring a support person. Medical appointments are high-stakes environments in which patients may feel pressured to defer to clinical authority. A trusted support person can help ensure questions are asked, answers are recorded, and follow-up steps are confirmed before leaving the office.

Seek a second opinion when necessary. If a physician dismisses concerns about G6PD deficiency without ordering appropriate testing, patients are entitled to seek evaluation from a hematologist or a physician with experience in genetic disorders.

The Policy Dimension: Advocating Beyond the Exam Room

Individual advocacy matters, but structural change requires policy intervention. Patient advocates and rare disease organizations have identified several priority areas for reform.

Expanding newborn screening panels to include G6PD deficiency in all fifty states would represent the single highest-impact intervention. Advocacy organizations are currently working with state health departments to build the evidence base for inclusion and to address cost concerns through economies of scale.

Increasing funding for provider education—through continuing medical education requirements, residency training updates, and targeted outreach to emergency medicine and primary care physicians—would reduce the knowledge gap that drives misdiagnosis.

Finally, ensuring that genetic counseling services are covered under Medicaid and accessible in underserved communities would address the equity dimension of the diagnostic delay problem.

Knowledge as a Tool for Change

G6PD deficiency is not a rare condition. It is a common genetic disorder that has been systematically deprioritized. Every patient who receives a delayed diagnosis, every hemolytic crisis that could have been prevented, every family that navigates years of medical uncertainty without answers—these outcomes are not inevitable. They are the product of specific, addressable failures in the healthcare system.

The mission of G6PD Awareness is to place knowledge directly in the hands of patients and families who need it most. Understanding the barriers to diagnosis is not an exercise in frustration—it is the foundation of effective advocacy. Armed with the right information, patients can demand faster answers, hold systems accountable, and ultimately change the trajectory of their own care.